GSK Lotronex Limited-Access Program Revisited By FDA In Patient Letter
FDA is revisiting the dispute over a limited-access program for GlaxoSmithKline's withdrawn irritable bowel syndrome drugLotronex
FDA is revisiting the dispute over a limited-access program for GlaxoSmithKline's withdrawn irritable bowel syndrome drugLotronex